免疫の先天性欠陥に対する遺伝子治療:過去の進展,現在の状態,将来の方向性
Robert Torrance1, Kate Orf1,2, Thomas A Fox1,2
1UCL Institute of Immunity and Transplantation, UCL, London NW3 2PP, United Kingdom.
まとめ
遺伝子療法 (GT) は,遺伝的欠陥を修正して,免疫の先天性エラー (IEI) に対する,ドナーから独立した,安全で効果的な治療法を提供します. このレビューは,40年間の進歩,現在の遺伝子編集技術,IEI治療の将来の方向性を強調しています.
科学分野:
- 免疫学 免疫学とは
- 遺伝学 遺伝学とは
- 医学科学 医学科学 医学科学 医学科学
背景:
- 免疫の先天性エラー (IEI) は,重度の感染症,自己免疫,悪性腫瘍を引き起こす珍しい遺伝疾患です.
- アロゲン血型造血幹細胞移植 (alloHSCT) は主要な治療法ですが,ドナーを必要とし,リスクがあります.
- オートロゴス遺伝子療法 (GT) は,患者の自身の細胞を利用し,ドナーの必要性とalloHSCTの合併症を回避します.
研究 の 目的:
- 過去40年間,免疫の先天性エラー (IEI) に対する遺伝子療法 (GT) の進展をレビューする.
- IEIを修正するための現在の遺伝子編集技術について説明する.
- IEI遺伝子療法における進歩,課題,および将来の方向性を検討する.
主な方法:
- IEIに対する遺伝子治療に関する臨床前および臨床試験のレビュー.
- IEI矯正のための遺伝子編集技術 (CRISPR-Cas9など) の分析.
- 課題と新たな in vivo アプローチの議論.
主要な成果:
- 遺伝子治療は,様々なIEIの修正において安全性と有効性を実証しています.
- 遺伝子編集技術は,IEIにおける遺伝的欠陥の正確な修正を提供します.
- 継続的な開発と新興の in vivo 戦略により,著しい進展がありました.
結論:
- オートログの遺伝子治療は,IEIのalloHSCTに対する安全で効果的な代替手段です.
- 遺伝子編集技術は,IEIの治療を進めています.
- インビヴォ遺伝子療法を含む将来の開発は,より広範なIEI治療に希望を示しています.
関連する概念動画
Gene Therapy
27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Microorganisms in Medicine and Therapeutics
1.2K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.2K
What is Genetic Engineering?
80.4K
Overview
80.4K
Development of Immunocompetence
1.0K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.0K
Immunodeficiency Diseases
2.5K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
2.5K
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K


